Is Modified GRF 1-29 legal in the United Kingdom?

Sold as CJC-1295 without DAC, which is a contradiction: the DAC is what makes a molecule CJC-1295. The human trial everyone quotes, 2 to 10 fold higher growth hormone for 6 days or more with a half-life of 5.8 to 8.1 days, was run on the DAC form. No human trial of the version without the DAC has been located.

Start with the naming, because the naming is the error. The 2005 paper that created CJC-1295 tested three maleimido derivatives of human growth hormone releasing factor 1-29 designed to bond to the free thiol on cysteine 34 of serum albumin.

Mechanism: A growth hormone releasing hormone analogue acting at the GHRH receptor on anterior pituitary somatotrophs to trigger growth hormone release, which raises IGF-1 downstream. The tetrasubstitution of the native GRF 1-29 sequence resists dipeptidyl peptidase IV cleavage, extending the peptide's survival in plasma from minutes to somewhat longer, but it does not confer albumin binding.

Regulatory history: Not approved for any indication and not evaluated. Sermorelin, the unmodified GRF 1-29, was an approved medicine in the United States and is no longer marketed in its original form. Tesamorelin, a different GHRH analogue, is approved for HIV-associated lipodystrophy.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Modified GRF 1-29 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.